Core Insights - Mirxes Holding Company Limited has completed the enrollment for its prospective clinical study CADENCE CRC, marking a significant milestone as it transitions to laboratory analysis and data evaluation, with results expected by 2026 [1][2] Group 1: Study Overview - The CADENCE CRC study, initiated in 2023, aims to recruit 6,000 participants from diverse ethnic backgrounds in Southeast Asia, enhancing the universality and clinical relevance of the data [2] - This study utilizes colonoscopy as the gold standard to rigorously assess the effectiveness and safety of Mirxes' blood test for colorectal cancer, driven by its proprietary miRNA multi-omics platform [2] - CADENCE CRC is noted as the largest blood-based colorectal cancer screening clinical study in the ASEAN region, focusing on early screening, which differentiates it from other approved products in the market [2] Group 2: Market Context - The Asian colorectal cancer screening market has surpassed 100 billion yuan, with a growing demand for non-invasive, convenient, and precise blood tests, positioning Mirxes' offerings to fill a significant market gap [2][3] - Single cancer screening remains dominant in the global early screening market, supported by clear clinical evidence and regulatory pathways, while multi-cancer screening faces challenges in clinical validation [3] Group 3: Technological Advantage - Mirxes leverages its unique miRNA technology platform to differentiate itself in a competitive early screening landscape, achieving commercialization that few global companies have accomplished [4] - The company targets the ASEAN and China markets, addressing the low screening coverage due to accessibility and resource distribution issues, thereby establishing a comprehensive clinical and commercial network in Asia [4]

CADENCE CRC于东南亚招募逾6000名受试者，是该地区首项且规模最大用以评估基于血液检测结直肠 癌筛查测试的注册性研究。该研究的受试者涵盖华裔、马来裔及印度裔等多种族裔背景，反映东南亚的 真实世界人口结构且强化研究发现的普适性。 CADENCE CRC设计为一项前瞻性验证研究，旨在支持本公司结直肠癌筛查血液检测获得监管批准及临 床采用。受试者接受标准治疗的结肠镜检查作为参考手段，从而实现对临床表现的严谨评估。 智通财经APP讯，MIRXES-B(02629)发布公告，本公司已完成CADENCE(CAncer Detected Early caN be CurEd) CRC的入组程序，CADENCE CRC是一项大型前瞻性临床研究，旨在验证其血液检测于平均风 险及高风险成人群体中筛查结直肠癌(结直肠癌)的有效性。 招募工作始于2023年，并于2026年初达成6000例的目标入组规模。完成入组标志着实现关键里程碑，研 究将进入后期实验室分析与数据评估阶段。本公司预期在完成数据分析及随访后于2026年内公布主要研 究结果。 CADENCE CRC中评估的血液检测由本公司专有的以miRNA为中心的多组学平台驱 ...